The antithrombotic effects of CI-1028, an orally bioavailable direct thrombin inhibitor, in a canine model of venous and arterial thrombosis

Direct thrombin inhibitors represent a new class of drug that may offer a therapeutic alternative for the treatment and prevention of thrombembolic conditions, especially on the venous side of the systemic circulation. CI-1028 (PD 172524/LB30057) is a potent, highly selective inhibitor of thrombin t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of thrombosis and thrombolysis 2000-12, Vol.10 (3), p.277-284
Hauptverfasser: MCCLANAHAN, Thomas B, HICKS, Gary W, IGNASIAK, Diane P, BOUSLEY, Richard, MERTZ, Thomas E, JUNEAU, Paul, JANICZEK-DOLPHIN, Nancy, KIM, In-Chull, GALLAGHER, Kim P
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 284
container_issue 3
container_start_page 277
container_title Journal of thrombosis and thrombolysis
container_volume 10
creator MCCLANAHAN, Thomas B
HICKS, Gary W
IGNASIAK, Diane P
BOUSLEY, Richard
MERTZ, Thomas E
JUNEAU, Paul
JANICZEK-DOLPHIN, Nancy
KIM, In-Chull
GALLAGHER, Kim P
description Direct thrombin inhibitors represent a new class of drug that may offer a therapeutic alternative for the treatment and prevention of thrombembolic conditions, especially on the venous side of the systemic circulation. CI-1028 (PD 172524/LB30057) is a potent, highly selective inhibitor of thrombin that is orally bioavailable. The efficacy of this compound has been demonstrated in animal models in which intra-venous administration was used. The objective of this study was to evaluate the efficacy of CI-1028 after oral administration in a canine electrolytic injury model of venous and arterial thrombosis. CI-1028 was administered via oral gavage, and animals received either saline or 10, 15, 20, or 30 mg/kg of drug. Fifteen minutes later, the dogs were anesthetized and a femoral artery and vein were exposed and instrumented to induce electrolytic injury and thrombosis while continuously monitoring blood flow in the vessels. Maximum blood CI-1028 concentrations of 0.88+/-0.27, 1.8+/-0.3, 2.2+/-0.5, and 3.2+/-0.5 microg/mL were generally achieved 15 to 30 minutes after administering the compound in the 10-, 15-, 20-, and 30-mg/kg groups, respectively. Administration of CI-1028 increased the time to occlusion (TTO), the principal efficacy end point, in a dose-dependent manner in both arteries and veins. The TTO in the control group (n=8) averaged 66+/-11 minutes in the arteries and 69+/-6 minutes in the veins. In dogs treated with 10 mg/kg (n=8), the TTO was not significantly different from that of the control group. In the 15-mg/kg group (n=9) TTO averaged 140+/-27 minutes in the arteries (p=not significant) and 125+/-15 minutes (p
doi_str_mv 10.1023/A:1026555510258
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_72480051</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72480051</sourcerecordid><originalsourceid>FETCH-LOGICAL-c308t-f9738862bd7c355a5422191566fc818caf31e94b05669fa6206fbd0382943e263</originalsourceid><addsrcrecordid>eNpdkEtLJTEQhYMoen2s3Q1BwZWteXTSiTu5ODOC4EbBXVOdTriRdKJJX8H_4I824h0XU7U4RfHV4VAIHVNyQQnjl9dXVaSoVVWoLbSgouNN17KnbbQgmulGcCL20H4pz4QQrQnbRXuUUsZEqxfo42FlMcTZz6ucpiHN3mDrnDVzwcnh5W1TjdV5RXDKEMI7HnyCN_ABhmDx6HNF8fexj9jHlR_8nPJ5HTFgA9FHi6c02vDl92ZjWpfqNmLIs80ewuY4FV8O0Y6DUOzRRg_Q4--bh-Xf5u7-z-3y-q4xnKi5cbrjSkk2jJ3hQoBoGaOaCimdUVQZcJxa3Q6kbrQDyYh0w0i4Yrrllkl-gM6-fV9yel3bMveTL8aGANHWeH3HWkWIoBU8-Q98Tusca7aeMcJry65CvzbQepjs2L9kP0F-7_89uQKnGwCKgeAyROPLD6daJZXgn4jhiek</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>220303067</pqid></control><display><type>article</type><title>The antithrombotic effects of CI-1028, an orally bioavailable direct thrombin inhibitor, in a canine model of venous and arterial thrombosis</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>MCCLANAHAN, Thomas B ; HICKS, Gary W ; IGNASIAK, Diane P ; BOUSLEY, Richard ; MERTZ, Thomas E ; JUNEAU, Paul ; JANICZEK-DOLPHIN, Nancy ; KIM, In-Chull ; GALLAGHER, Kim P</creator><creatorcontrib>MCCLANAHAN, Thomas B ; HICKS, Gary W ; IGNASIAK, Diane P ; BOUSLEY, Richard ; MERTZ, Thomas E ; JUNEAU, Paul ; JANICZEK-DOLPHIN, Nancy ; KIM, In-Chull ; GALLAGHER, Kim P</creatorcontrib><description>Direct thrombin inhibitors represent a new class of drug that may offer a therapeutic alternative for the treatment and prevention of thrombembolic conditions, especially on the venous side of the systemic circulation. CI-1028 (PD 172524/LB30057) is a potent, highly selective inhibitor of thrombin that is orally bioavailable. The efficacy of this compound has been demonstrated in animal models in which intra-venous administration was used. The objective of this study was to evaluate the efficacy of CI-1028 after oral administration in a canine electrolytic injury model of venous and arterial thrombosis. CI-1028 was administered via oral gavage, and animals received either saline or 10, 15, 20, or 30 mg/kg of drug. Fifteen minutes later, the dogs were anesthetized and a femoral artery and vein were exposed and instrumented to induce electrolytic injury and thrombosis while continuously monitoring blood flow in the vessels. Maximum blood CI-1028 concentrations of 0.88+/-0.27, 1.8+/-0.3, 2.2+/-0.5, and 3.2+/-0.5 microg/mL were generally achieved 15 to 30 minutes after administering the compound in the 10-, 15-, 20-, and 30-mg/kg groups, respectively. Administration of CI-1028 increased the time to occlusion (TTO), the principal efficacy end point, in a dose-dependent manner in both arteries and veins. The TTO in the control group (n=8) averaged 66+/-11 minutes in the arteries and 69+/-6 minutes in the veins. In dogs treated with 10 mg/kg (n=8), the TTO was not significantly different from that of the control group. In the 15-mg/kg group (n=9) TTO averaged 140+/-27 minutes in the arteries (p=not significant) and 125+/-15 minutes (p&lt;0.05) in the veins. In the 20-mg/kg group (n=8), TTO was significantly longer than controls in both types of vessels, averaging 168+/-30 minutes in the arteries (p=0.05) and 155+/-21 minutes (p&lt;0.05) in the veins. Likewise, at 30 mg/kg (n=8) both the arterial (179+/-17 minutes) and venous (188+/-15 minutes) TTO was significantly prolonged compared with controls. Surgical blood loss and template bleeding times tended to increase in a dose-dependent manner but a statistically significant elevation was detected for template bleeding time only at the highest dose. Dramatic changes in thrombin time were detected, consistent with the CI-1028 mechanism of action. Virtually no changes were detected in prothrombin time. Maximum activated partial thromboplastin time (aPTT) and activated clotting time changes were detected approximately 30 minutes after dosing, and they were approximately twofold and fivefold baseline values, respectively, at the highest dose. In conclusion, these results demonstrate that CI-1028 provides dose-dependent antithrombotic efficacy after oral administration in a canine model of venous and arterial thrombosis.</description><identifier>ISSN: 0929-5305</identifier><identifier>EISSN: 1573-742X</identifier><identifier>DOI: 10.1023/A:1026555510258</identifier><identifier>PMID: 11122549</identifier><identifier>CODEN: JTTHFF</identifier><language>eng</language><publisher>Heidelberg: Springer</publisher><subject>Administration, Oral ; Animals ; Arterial Occlusive Diseases ; Benzamides - pharmacokinetics ; Benzamides - pharmacology ; Biological and medical sciences ; Biological Availability ; Blood Coagulation Tests ; Blood Flow Velocity - drug effects ; Blood Loss, Surgical ; Blood. Blood coagulation. Reticuloendothelial system ; Disease Models, Animal ; Dogs ; Dose-Response Relationship, Drug ; Fibrinolytic Agents - administration &amp; dosage ; Fibrinolytic Agents - pharmacology ; Hemorrhage - chemically induced ; Medical sciences ; Pharmacology. Drug treatments ; Thrombin - antagonists &amp; inhibitors ; Thrombosis - drug therapy ; Venous Thrombosis</subject><ispartof>Journal of thrombosis and thrombolysis, 2000-12, Vol.10 (3), p.277-284</ispartof><rights>2001 INIST-CNRS</rights><rights>Copyright Kluwer Academic Publishers Dec 2000</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c308t-f9738862bd7c355a5422191566fc818caf31e94b05669fa6206fbd0382943e263</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=848685$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11122549$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>MCCLANAHAN, Thomas B</creatorcontrib><creatorcontrib>HICKS, Gary W</creatorcontrib><creatorcontrib>IGNASIAK, Diane P</creatorcontrib><creatorcontrib>BOUSLEY, Richard</creatorcontrib><creatorcontrib>MERTZ, Thomas E</creatorcontrib><creatorcontrib>JUNEAU, Paul</creatorcontrib><creatorcontrib>JANICZEK-DOLPHIN, Nancy</creatorcontrib><creatorcontrib>KIM, In-Chull</creatorcontrib><creatorcontrib>GALLAGHER, Kim P</creatorcontrib><title>The antithrombotic effects of CI-1028, an orally bioavailable direct thrombin inhibitor, in a canine model of venous and arterial thrombosis</title><title>Journal of thrombosis and thrombolysis</title><addtitle>J Thromb Thrombolysis</addtitle><description>Direct thrombin inhibitors represent a new class of drug that may offer a therapeutic alternative for the treatment and prevention of thrombembolic conditions, especially on the venous side of the systemic circulation. CI-1028 (PD 172524/LB30057) is a potent, highly selective inhibitor of thrombin that is orally bioavailable. The efficacy of this compound has been demonstrated in animal models in which intra-venous administration was used. The objective of this study was to evaluate the efficacy of CI-1028 after oral administration in a canine electrolytic injury model of venous and arterial thrombosis. CI-1028 was administered via oral gavage, and animals received either saline or 10, 15, 20, or 30 mg/kg of drug. Fifteen minutes later, the dogs were anesthetized and a femoral artery and vein were exposed and instrumented to induce electrolytic injury and thrombosis while continuously monitoring blood flow in the vessels. Maximum blood CI-1028 concentrations of 0.88+/-0.27, 1.8+/-0.3, 2.2+/-0.5, and 3.2+/-0.5 microg/mL were generally achieved 15 to 30 minutes after administering the compound in the 10-, 15-, 20-, and 30-mg/kg groups, respectively. Administration of CI-1028 increased the time to occlusion (TTO), the principal efficacy end point, in a dose-dependent manner in both arteries and veins. The TTO in the control group (n=8) averaged 66+/-11 minutes in the arteries and 69+/-6 minutes in the veins. In dogs treated with 10 mg/kg (n=8), the TTO was not significantly different from that of the control group. In the 15-mg/kg group (n=9) TTO averaged 140+/-27 minutes in the arteries (p=not significant) and 125+/-15 minutes (p&lt;0.05) in the veins. In the 20-mg/kg group (n=8), TTO was significantly longer than controls in both types of vessels, averaging 168+/-30 minutes in the arteries (p=0.05) and 155+/-21 minutes (p&lt;0.05) in the veins. Likewise, at 30 mg/kg (n=8) both the arterial (179+/-17 minutes) and venous (188+/-15 minutes) TTO was significantly prolonged compared with controls. Surgical blood loss and template bleeding times tended to increase in a dose-dependent manner but a statistically significant elevation was detected for template bleeding time only at the highest dose. Dramatic changes in thrombin time were detected, consistent with the CI-1028 mechanism of action. Virtually no changes were detected in prothrombin time. Maximum activated partial thromboplastin time (aPTT) and activated clotting time changes were detected approximately 30 minutes after dosing, and they were approximately twofold and fivefold baseline values, respectively, at the highest dose. In conclusion, these results demonstrate that CI-1028 provides dose-dependent antithrombotic efficacy after oral administration in a canine model of venous and arterial thrombosis.</description><subject>Administration, Oral</subject><subject>Animals</subject><subject>Arterial Occlusive Diseases</subject><subject>Benzamides - pharmacokinetics</subject><subject>Benzamides - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Biological Availability</subject><subject>Blood Coagulation Tests</subject><subject>Blood Flow Velocity - drug effects</subject><subject>Blood Loss, Surgical</subject><subject>Blood. Blood coagulation. Reticuloendothelial system</subject><subject>Disease Models, Animal</subject><subject>Dogs</subject><subject>Dose-Response Relationship, Drug</subject><subject>Fibrinolytic Agents - administration &amp; dosage</subject><subject>Fibrinolytic Agents - pharmacology</subject><subject>Hemorrhage - chemically induced</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Thrombin - antagonists &amp; inhibitors</subject><subject>Thrombosis - drug therapy</subject><subject>Venous Thrombosis</subject><issn>0929-5305</issn><issn>1573-742X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpdkEtLJTEQhYMoen2s3Q1BwZWteXTSiTu5ODOC4EbBXVOdTriRdKJJX8H_4I824h0XU7U4RfHV4VAIHVNyQQnjl9dXVaSoVVWoLbSgouNN17KnbbQgmulGcCL20H4pz4QQrQnbRXuUUsZEqxfo42FlMcTZz6ucpiHN3mDrnDVzwcnh5W1TjdV5RXDKEMI7HnyCN_ABhmDx6HNF8fexj9jHlR_8nPJ5HTFgA9FHi6c02vDl92ZjWpfqNmLIs80ewuY4FV8O0Y6DUOzRRg_Q4--bh-Xf5u7-z-3y-q4xnKi5cbrjSkk2jJ3hQoBoGaOaCimdUVQZcJxa3Q6kbrQDyYh0w0i4Yrrllkl-gM6-fV9yel3bMveTL8aGANHWeH3HWkWIoBU8-Q98Tusca7aeMcJry65CvzbQepjs2L9kP0F-7_89uQKnGwCKgeAyROPLD6daJZXgn4jhiek</recordid><startdate>20001201</startdate><enddate>20001201</enddate><creator>MCCLANAHAN, Thomas B</creator><creator>HICKS, Gary W</creator><creator>IGNASIAK, Diane P</creator><creator>BOUSLEY, Richard</creator><creator>MERTZ, Thomas E</creator><creator>JUNEAU, Paul</creator><creator>JANICZEK-DOLPHIN, Nancy</creator><creator>KIM, In-Chull</creator><creator>GALLAGHER, Kim P</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20001201</creationdate><title>The antithrombotic effects of CI-1028, an orally bioavailable direct thrombin inhibitor, in a canine model of venous and arterial thrombosis</title><author>MCCLANAHAN, Thomas B ; HICKS, Gary W ; IGNASIAK, Diane P ; BOUSLEY, Richard ; MERTZ, Thomas E ; JUNEAU, Paul ; JANICZEK-DOLPHIN, Nancy ; KIM, In-Chull ; GALLAGHER, Kim P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c308t-f9738862bd7c355a5422191566fc818caf31e94b05669fa6206fbd0382943e263</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Administration, Oral</topic><topic>Animals</topic><topic>Arterial Occlusive Diseases</topic><topic>Benzamides - pharmacokinetics</topic><topic>Benzamides - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Biological Availability</topic><topic>Blood Coagulation Tests</topic><topic>Blood Flow Velocity - drug effects</topic><topic>Blood Loss, Surgical</topic><topic>Blood. Blood coagulation. Reticuloendothelial system</topic><topic>Disease Models, Animal</topic><topic>Dogs</topic><topic>Dose-Response Relationship, Drug</topic><topic>Fibrinolytic Agents - administration &amp; dosage</topic><topic>Fibrinolytic Agents - pharmacology</topic><topic>Hemorrhage - chemically induced</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Thrombin - antagonists &amp; inhibitors</topic><topic>Thrombosis - drug therapy</topic><topic>Venous Thrombosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>MCCLANAHAN, Thomas B</creatorcontrib><creatorcontrib>HICKS, Gary W</creatorcontrib><creatorcontrib>IGNASIAK, Diane P</creatorcontrib><creatorcontrib>BOUSLEY, Richard</creatorcontrib><creatorcontrib>MERTZ, Thomas E</creatorcontrib><creatorcontrib>JUNEAU, Paul</creatorcontrib><creatorcontrib>JANICZEK-DOLPHIN, Nancy</creatorcontrib><creatorcontrib>KIM, In-Chull</creatorcontrib><creatorcontrib>GALLAGHER, Kim P</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of thrombosis and thrombolysis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>MCCLANAHAN, Thomas B</au><au>HICKS, Gary W</au><au>IGNASIAK, Diane P</au><au>BOUSLEY, Richard</au><au>MERTZ, Thomas E</au><au>JUNEAU, Paul</au><au>JANICZEK-DOLPHIN, Nancy</au><au>KIM, In-Chull</au><au>GALLAGHER, Kim P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The antithrombotic effects of CI-1028, an orally bioavailable direct thrombin inhibitor, in a canine model of venous and arterial thrombosis</atitle><jtitle>Journal of thrombosis and thrombolysis</jtitle><addtitle>J Thromb Thrombolysis</addtitle><date>2000-12-01</date><risdate>2000</risdate><volume>10</volume><issue>3</issue><spage>277</spage><epage>284</epage><pages>277-284</pages><issn>0929-5305</issn><eissn>1573-742X</eissn><coden>JTTHFF</coden><abstract>Direct thrombin inhibitors represent a new class of drug that may offer a therapeutic alternative for the treatment and prevention of thrombembolic conditions, especially on the venous side of the systemic circulation. CI-1028 (PD 172524/LB30057) is a potent, highly selective inhibitor of thrombin that is orally bioavailable. The efficacy of this compound has been demonstrated in animal models in which intra-venous administration was used. The objective of this study was to evaluate the efficacy of CI-1028 after oral administration in a canine electrolytic injury model of venous and arterial thrombosis. CI-1028 was administered via oral gavage, and animals received either saline or 10, 15, 20, or 30 mg/kg of drug. Fifteen minutes later, the dogs were anesthetized and a femoral artery and vein were exposed and instrumented to induce electrolytic injury and thrombosis while continuously monitoring blood flow in the vessels. Maximum blood CI-1028 concentrations of 0.88+/-0.27, 1.8+/-0.3, 2.2+/-0.5, and 3.2+/-0.5 microg/mL were generally achieved 15 to 30 minutes after administering the compound in the 10-, 15-, 20-, and 30-mg/kg groups, respectively. Administration of CI-1028 increased the time to occlusion (TTO), the principal efficacy end point, in a dose-dependent manner in both arteries and veins. The TTO in the control group (n=8) averaged 66+/-11 minutes in the arteries and 69+/-6 minutes in the veins. In dogs treated with 10 mg/kg (n=8), the TTO was not significantly different from that of the control group. In the 15-mg/kg group (n=9) TTO averaged 140+/-27 minutes in the arteries (p=not significant) and 125+/-15 minutes (p&lt;0.05) in the veins. In the 20-mg/kg group (n=8), TTO was significantly longer than controls in both types of vessels, averaging 168+/-30 minutes in the arteries (p=0.05) and 155+/-21 minutes (p&lt;0.05) in the veins. Likewise, at 30 mg/kg (n=8) both the arterial (179+/-17 minutes) and venous (188+/-15 minutes) TTO was significantly prolonged compared with controls. Surgical blood loss and template bleeding times tended to increase in a dose-dependent manner but a statistically significant elevation was detected for template bleeding time only at the highest dose. Dramatic changes in thrombin time were detected, consistent with the CI-1028 mechanism of action. Virtually no changes were detected in prothrombin time. Maximum activated partial thromboplastin time (aPTT) and activated clotting time changes were detected approximately 30 minutes after dosing, and they were approximately twofold and fivefold baseline values, respectively, at the highest dose. In conclusion, these results demonstrate that CI-1028 provides dose-dependent antithrombotic efficacy after oral administration in a canine model of venous and arterial thrombosis.</abstract><cop>Heidelberg</cop><pub>Springer</pub><pmid>11122549</pmid><doi>10.1023/A:1026555510258</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0929-5305
ispartof Journal of thrombosis and thrombolysis, 2000-12, Vol.10 (3), p.277-284
issn 0929-5305
1573-742X
language eng
recordid cdi_proquest_miscellaneous_72480051
source MEDLINE; SpringerNature Journals
subjects Administration, Oral
Animals
Arterial Occlusive Diseases
Benzamides - pharmacokinetics
Benzamides - pharmacology
Biological and medical sciences
Biological Availability
Blood Coagulation Tests
Blood Flow Velocity - drug effects
Blood Loss, Surgical
Blood. Blood coagulation. Reticuloendothelial system
Disease Models, Animal
Dogs
Dose-Response Relationship, Drug
Fibrinolytic Agents - administration & dosage
Fibrinolytic Agents - pharmacology
Hemorrhage - chemically induced
Medical sciences
Pharmacology. Drug treatments
Thrombin - antagonists & inhibitors
Thrombosis - drug therapy
Venous Thrombosis
title The antithrombotic effects of CI-1028, an orally bioavailable direct thrombin inhibitor, in a canine model of venous and arterial thrombosis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T17%3A22%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20antithrombotic%20effects%20of%20CI-1028,%20an%20orally%20bioavailable%20direct%20thrombin%20inhibitor,%20in%20a%20canine%20model%20of%20venous%20and%20arterial%20thrombosis&rft.jtitle=Journal%20of%20thrombosis%20and%20thrombolysis&rft.au=MCCLANAHAN,%20Thomas%20B&rft.date=2000-12-01&rft.volume=10&rft.issue=3&rft.spage=277&rft.epage=284&rft.pages=277-284&rft.issn=0929-5305&rft.eissn=1573-742X&rft.coden=JTTHFF&rft_id=info:doi/10.1023/A:1026555510258&rft_dat=%3Cproquest_pubme%3E72480051%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=220303067&rft_id=info:pmid/11122549&rfr_iscdi=true